^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vindesine

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    β-tubulin inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients (clinicaltrials.gov)
    P2, N=27, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • dexamethasone • vindesine
    4ms
    Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (clinicaltrials.gov)
    P2, N=26, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vindesine
    5ms
    Adult pancreatoblastoma: Systematic review of the literature and case report of a young adult patient. (PubMed, World J Gastrointest Oncol)
    Common pancreatoblastoma features include acinar groups, chromogranin, chymotrypsin, squamous corpuscles, synaptophysin and trypsin on histology and adenomatous polyposis coli, B-cell lymphoma/leukemia 10, catenin beta 1, and Wnt/beta-catenin genetic mutations.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SYP (Synaptophysin)
    |
    cisplatin • carboplatin • gemcitabine • 5-fluorouracil • doxorubicin hydrochloride • mitomycin • bleomycin • vindesine
    5ms
    Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (clinicaltrials.gov)
    P2/3, N=50, Recruiting, Shanxi Bethune Hospital
    New P2/3 trial
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • vindesine
    7ms
    Weekly Vindesine as Second-line Chemotherapy in Pediatric Low-Grade Glioma (ChiCTR2500102311)
    P=N/A, N=3, Not yet recruiting, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center, Shanghai Jiao Tong Universit
    New trial
    |
    vindesine
    7ms
    FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration (clinicaltrials.gov)
    P3, N=102, Not yet recruiting, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    carboplatin • temozolomide • Ivesa (firmonertinib) • luvometinib (FCN-159) • vindesine
    8ms
    Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. (PubMed, JAMA Oncol)
    Dasatinib was administered with a 2-week vindesine and dexamethasone regimen as induction, followed by sequential CD19 and CD22 CAR T-cell therapies and single-agent dasatinib maintenance. The primary end point was CMR rate after CD19 CAR T-cell therapy...Further studies with larger cohorts and longer follow-up durations are needed. ClinicalTrials.gov Identifier: NCT04788472.
    Clinical • Journal
    |
    ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
    |
    dasatinib • dexamethasone • CD19/CD22 CAR-T cell therapy • anti-CD22 CAR-T cell therapy • vindesine
    8ms
    Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=58, Not yet recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    Gazyva (obinutuzumab) • cyclophosphamide • Brukinsa (zanubrutinib) • vindesine
    9ms
    A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of teniposide combined with RCHOP in newly diagnosed diffuse large B-cell lymphoma patients with high risk of central nervous system relapse (ChiCTR2500099874)
    P=N/A, N=47, Not yet recruiting, The first affiliated hospital Zhejiang University school of medicine; The first affiliated hospital Zhejiang University school of medicine
    New trial
    |
    CD5 (CD5 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Vumon (teniposide) • vindesine
    9ms
    A multicenter randomized study of safety and efficacy of MAPK pathway inhibition as first-line therapy in the treatment of pediatric Langerhans cell histiocytosis (ChiCTR2500097759)
    P1, N=212, Not yet recruiting, Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University
    New P1 trial
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • vindesine
    9ms
    B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (clinicaltrials.gov)
    P3, N=650, Active, not recruiting, University Hospital Muenster | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Jun 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • vindesine
    10ms
    LBL-2016 for Children or Adolescents in China (clinicaltrials.gov)
    P3, N=150, Active, not recruiting, Children's Cancer Group, China | Trial completion date: Dec 2025 --> Dec 2031
    Trial completion date
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • mercaptopurine • vindesine